Phase III Randomized Controlled Open Label Clinical Trial to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer
Randomized trial that compares a personalized digitally-enabled pathway delivered by a mobile application in addition to standard of care vs. standard of care alone in patients with HR+ early breast cancer reporting endocrine therapy related adverse events. The HOPE study is a national, prospective, randomized, open-label trial conducted in France. 180 patients will be randomly assigned 1:1 to receive either 12 weeks of multimodal Resilience© digital companion including education and self-care modules in addition to the standard of care provided by their treating oncologists and supportive care team at their care centers or 12 weeks of standard of care provided by their treating oncologists and supportive care team at their care centers. Data from the literature in oncology trials with Patient-Reported Outcomes suggests that in the absence of double-blind concealment, clinically important differences could still be detected.
• Documentation of Disease:
‣ Subjects must have histologically confirmed ER and/or PgR positive HR+ invasive BC;
⁃ Subjects must have stage I to III breast cancer and no evidence of distant metastatic or locally recurrent disease;
• NB: Bilateral breast carcinoma is allowed;
• NB: Patients with personal history of previous breast cancer or Ductal Carcinoma in situ (DCIS) are eligible for the protocol;
• Indication to receive adjuvant endocrine therapy (tamoxifen or aromatase inhibitors) with or without targeted agents (e.g., CDK 4/6 inhibitors, PARP inhibitors, bisphosphonates);
• Prior treatment: Patients must be actively on ET for their breast cancer diagnosis (any type, including either tamoxifen or an aromatase-inhibitor with or without targeted agents) at the time of study enrollment;
• Documentation of side effects of ongoing ET: Any endocrine therapy related adverse effects should be reported during treatment with endocrine therapy;
• Others:
‣ Age ≥ 18 years;
⁃ ECOG Performance Status 0,1 or 2;
⁃ Patients should possess a smartphone;
⁃ Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed;
⁃ Patient should be able and willing to comply with study visits and procedures as per protocol;
⁃ Patients must be affiliated to a social security system or beneficiary of the same;
⁃ Able to readily read and understand French;
∙ NB: Patients may have breast reconstruction during protocol participation;
∙ NB: Biologic therapy, targeted therapy and bisphosphonates are acceptable during protocol participation;
∙ NB: Male patients can be included in the trial;
∙ NB: Pharmacological or other non-pharmacological interventions for endocrine treatment for adverse effects are accepted at physician discretion.